Allarity Therapeutics, Inc. (ALLR)Healthcare | Biotechnology | Tarpon Springs, United States | NasdaqCM
1.13 USD
-0.04
(-3.004%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.15 +0.02 (1.478%) ⇧ (July 13, 2026, 5:42 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:08 a.m. EDT
The investment case here is structurally broken. The company is burning through cash at an alarming rate, with free cash flow of nearly $21 million in the red and operating margins collapsing to -107%. While the balance sheet shows a tiny amount of cash, it is almost entirely offset by debt, leaving the entity with no financial runway and negative returns on both assets and equity. The price action confirms this deterioration, having lost virtually all its value over the last three years with three consecutive years of massive declines. There is no dividend to provide any income cushion, and the recent trading activity shows continued weakness, dropping below the 50-day average. Any hope of a turnaround relies entirely on future clinical trial success rather than current financial reality, making this a high-risk speculative play rather than a viable investment. |
| Model | MAE |
|---|---|
| MSTL_63 ✓ | 0.135561 |
| AutoETS | 0.151070 |
| MSTL_63_114 | 0.155011 |
| AutoARIMA | 0.156540 |
| MSTL | 0.157846 |
| MSTL_114 | 0.181650 |
| AutoTheta | 0.625560 |
Forecast horizon: 60 days | Selected: MSTL_63
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 0.45 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.470 |
| Excess Kurtosis | -0.77 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 310.636 |
| Revenue per Share | 0.022 |
| Market Cap | 17,979,118 |
| Forward P/E | -1.16 |
| Beta | 0.53 |
| Previous Name | Oncology Venture A/S |
| Website | https://www.allarity.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.10952377 |
| Address1 | 123 E. Tarpon Ave. |
| All Time High | 15,288,000.0 |
| All Time Low | 0.614 |
| Ask | 1.45 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 151,250 |
| Average Daily Volume3 Month | 200,411 |
| Average Volume | 200,411 |
| Average Volume10Days | 151,250 |
| Beta | 0.526 |
| Bid | 0.8352 |
| Bid Size | 2 |
| Book Value | 0.437 |
| City | Tarpon Springs |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.13 |
| Current Ratio | 1.232 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.17 |
| Day Low | 1.12 |
| Debt To Equity | 310.636 |
| Display Name | Allarity Therapeutics |
| Ebitda Margins | 0.0 |
| Enterprise To Revenue | 56.995 |
| Enterprise Value | 19,663,118 |
| Eps Current Year | -0.92 |
| Eps Forward | -0.97 |
| Eps Trailing Twelve Months | -0.68 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.453 |
| Fifty Day Average Change | -0.32299995 |
| Fifty Day Average Change Percent | -0.22229867 |
| Fifty Two Week Change Percent | 10.952377 |
| Fifty Two Week High | 2.35 |
| Fifty Two Week High Change | -1.2199999 |
| Fifty Two Week High Change Percent | -0.51914895 |
| Fifty Two Week Low | 0.769 |
| Fifty Two Week Low Change | 0.361 |
| Fifty Two Week Low Change Percent | 0.46944085 |
| Fifty Two Week Range | 0.769 - 2.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,640,097,000,000 |
| Float Shares | 15,610,489 |
| Forward Eps | -0.97 |
| Forward P E | -1.1649485 |
| Free Cashflow | -20,963,750 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 7 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 345,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0419 |
| Held Percent Institutions | 0.05975 |
| Implied Shares Outstanding | 15,910,724 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-12-21 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,726,012,800 |
| Last Split Factor | 1:30 |
| Long Business Summary | Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida. |
| Long Name | Allarity Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 17,979,118 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_225998297 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -11,249,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 18,535,993 |
| Number Of Analyst Opinions | 1 |
| Open | 1.15 |
| Operating Cashflow | -16,627,000 |
| Operating Margins | -107.52 |
| Payout Ratio | 0.0 |
| Phone | 401 426 4664 |
| Post Market Change | 0.01670003 |
| Post Market Change Percent | 1.4778787 |
| Post Market Price | 1.1467 |
| Post Market Time | 1,783,978,942 |
| Prev Name | Oncology Venture A/S |
| Previous Close | 1.165 |
| Price Eps Current Year | -1.2282609 |
| Price Hint | 4 |
| Price To Book | 2.5858123 |
| Price To Sales Trailing12 Months | 52.113384 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.746 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.035 |
| Regular Market Change Percent | -3.00429 |
| Regular Market Day High | 1.17 |
| Regular Market Day Low | 1.12 |
| Regular Market Day Range | 1.12 - 1.17 |
| Regular Market Open | 1.15 |
| Regular Market Previous Close | 1.165 |
| Regular Market Price | 1.13 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 69,731 |
| Return On Assets | -0.23698 |
| Return On Equity | -0.87921 |
| Revenue Per Share | 0.022 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 15,910,724 |
| Shares Percent Shares Out | 0.0050999997 |
| Shares Short | 80,824 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 175,238 |
| Short Name | Allarity Therapeutics, Inc. |
| Short Percent Of Float | 0.0050999997 |
| Short Ratio | 0.48 |
| Source Interval | 15 |
| State | FL |
| Symbol | ALLR |
| Target High Price | 10.25 |
| Target Low Price | 10.25 |
| Target Mean Price | 10.25 |
| Target Median Price | 10.25 |
| Total Cash | 19,812,000 |
| Total Cash Per Share | 1.245 |
| Total Debt | 21,496,000 |
| Total Revenue | 345,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.68 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.265805 |
| Two Hundred Day Average Change | -0.13580501 |
| Two Hundred Day Average Change Percent | -0.10728747 |
| Type Disp | Equity |
| Volume | 69,731 |
| Website | https://www.allarity.com |
| Zip | 34,689 |